CircZBTB46, a promising therapeutic target in crizotinib resistant ALK-positive T lymphomas
This preclinical study was triaged for T1 - Hematologic Malignancies based on abstract review. It appears standard priority because it addresses a direct clinical or diagnostic question with limited evidence maturity.
This preclinical study was triaged for T1 - Hematologic Malignancies based on abstract review. It appears standard priority because it addresses a direct clinical or diagnostic question with limited evidence maturity.
What the study was
- Study design
- Preclinical study
- Maturity
- Exploratory
- Journal
- Leukemia
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.